{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T03:46:39Z","timestamp":1795146399644,"version":"4.10.3"},"reference-count":44,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2023,10,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>The global prevalence of myopia is predicted to approach 50% by 2050, increasing the risk of visual impairment later in life. No pharmacologic therapy is approved for treating childhood myopia progression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To assess the safety and efficacy of NVK002 (Vyluma), a novel, preservative-free, 0.01% and 0.02% low-dose atropine formulation for treating myopia progression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This was a double-masked, placebo-controlled, parallel-group, randomized phase 3 clinical trial conducted from November 20, 2017, through August 22, 2022, of placebo vs low-dose atropine, 0.01% and 0.02% (2:2:3 ratio). Participants were recruited from 26 clinical sites in North America and 5 countries in Europe. Enrolled participants were 3 to 16 years of age with \u22120.50 diopter (D) to \u22126.00 D spherical equivalent refractive error (SER) and no worse than \u22121.50 D astigmatism.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>Once-daily placebo, low-dose atropine, 0.01%, or low-dose atropine, 0.02%, eye drops for 36 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary, prespecified end point was the proportion of participants\u2019 eyes responding to 0.02% atropine vs placebo therapy (&amp;amp;lt;0.50 D myopia progression at 36 months [responder analysis]). Secondary efficacy end points included responder analysis for atropine, 0.01%, and mean change from baseline in SER and axial length at month 36 in a modified intention-to-treat population (mITT; participants 6-10 years of age at baseline). Safety measurements for treated participants (3-16 years of age) were reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 576 participants were randomly assigned to treatment groups. Of these, 573 participants (99.5%; mean [SD] age, 8.9 [2.0] years; 315 female [54.7%]) received trial treatment (3 participants who were randomized did not receive trial drug) and were included in the safety set. The 489 participants (84.9%) who were 6 to 10 years of age at randomization composed the mITT set. At month 36, compared with placebo, low-dose atropine, 0.02%, did not significantly increase the responder proportion (odds ratio [OR], 1.77; 95% CI, 0.50-6.26; <jats:italic>P<\/jats:italic>\u2009=\u2009.37) or slow mean SER progression (least squares mean [LSM] difference, 0.10 D; 95% CI, \u22120.02 D to 0.22 D; <jats:italic>P<\/jats:italic>\u2009=\u2009.10) but did slow mean axial elongation (LSM difference, \u22120.08 mm; 95% CI, \u22120.13 mm to \u22120.02 mm; <jats:italic>P<\/jats:italic>\u2009=\u2009.005); however, at month 36, compared with placebo, low-dose atropine, 0.01%, significantly increased the responder proportion (OR, 4.54; 95% CI, 1.15-17.97; <jats:italic>P<\/jats:italic>\u2009=\u2009.03), slowed mean SER progression (LSM difference, 0.24 D; 95% CI, 0.11 D-0.37 D; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001), and slowed axial elongation (LSM difference, \u22120.13 mm; 95% CI, \u22120.19 mm to \u22120.07 mm; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001). There were no serious ocular adverse events and few serious nonocular events; none was judged as associated with atropine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>This randomized clinical trial found that 0.02% atropine did not significantly increase the proportion of participants\u2019 eyes responding to therapy but suggested efficacy for 0.01% atropine across all 3 main end points compared with placebo. The efficacy and safety observed suggest that low-dose atropine may provide a treatment option for childhood myopia progression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03350620\">NCT03350620<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2023.2097","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T15:32:48Z","timestamp":1685633568000},"page":"990","source":"Crossref","is-referenced-by-count":149,"title":["Efficacy and Safety of 0.01% and 0.02% Atropine for the Treatment of Pediatric Myopia Progression Over 3 Years"],"prefix":"10.1001","volume":"141","author":[{"given":"Karla","family":"Zadnik","sequence":"first","affiliation":[{"name":"The Ohio State University College of Optometry, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Schulman","sequence":"additional","affiliation":[{"name":"SUNY College of Optometry, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Flitcroft","sequence":"additional","affiliation":[{"name":"Centre for Eye Research, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Fogt","sequence":"additional","affiliation":[{"name":"The Ohio State University College of Optometry, Columbus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis C.","family":"Blumenfeld","sequence":"additional","affiliation":[{"name":"Eye Physicians of Central Florida, Maitland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tung M.","family":"Fong","sequence":"additional","affiliation":[{"name":"Vyluma Inc, Bridgewater, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lang","sequence":"additional","affiliation":[{"name":"Vyluma Inc, Bridgewater, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houman D.","family":"Hemmati","sequence":"additional","affiliation":[{"name":"Vyluma Inc, Bridgewater, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon P.","family":"Chandler","sequence":"additional","affiliation":[{"name":"Vyluma Inc, Bridgewater, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"CHAMP Trial Group Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Aune","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Ayet","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren J.","family":"Bell","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Bodack","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Colburn","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Cotter","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annegret","family":"Dahlmann-Noor","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Glaser","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hoekel","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Iacono","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Jenewein","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Klaver","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Lichtenstein","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunming","family":"Liu","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Loughman","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoltan","family":"Nagy","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Paul","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Schmitt","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Silbert","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Singh","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Twelker","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuensanta","family":"Vera-Diaz","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy","family":"Wang","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Willoughby","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikki","family":"Buck","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Bailey","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Schuck","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Ballering","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Spiegel","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuyen","family":"Ong","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milagros","family":"Nadal","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Novello","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kappelhof","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nestor","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Larkin","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Somberg","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Killian","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Castellana","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Crockett","sequence":"additional","affiliation":[{"name":"for the CHAMP Trial Group Investigators"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"5","key":"eoi230027r1","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","article-title":"Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050.","volume":"123","author":"Holden","year":"2016","journal-title":"Ophthalmology"},{"issue":"7","key":"eoi230027r2","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1136\/bjophthalmol-2017-311266","article-title":"Global prevalence of visual impairment associated with myopic macular degeneration and temporal trends from 2000 through 2050: systematic review, meta-analysis and modeling.","volume":"102","author":"Fricke","year":"2018","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"eoi230027r3","doi-asserted-by":"publisher","first-page":"M1","DOI":"10.1167\/iovs.18-25980","article-title":"IMI: myopia control reports overview and introduction.","volume":"60","author":"Wolffsohn","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"eoi230027r4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/OPX.0b013e3182357f79","article-title":"Myopia progression rates in urban children wearing single-vision spectacles.","volume":"89","author":"Donovan","year":"2012","journal-title":"Optom Vis Sci"},{"issue":"8","key":"eoi230027r5","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/aos.2014.92.issue-8","article-title":"The progression of myopia from its onset at age 8-12 to adulthood and the influence of heredity and external factors on myopic progression: a 23-year follow-up study.","volume":"92","author":"P\u00e4rssinen","year":"2014","journal-title":"Acta Ophthalmol"},{"issue":"5","key":"eoi230027r6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1167\/iovs.62.5.2","article-title":"IMI impact of myopia.","volume":"62","author":"Sankaridurg","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"eoi230027r7","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.ophtha.2021.04.032","article-title":"The risks and benefits of myopia control.","volume":"128","author":"Bullimore","year":"2021","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi230027r8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1167\/iovs.61.4.49","article-title":"The complications of myopia: a review and meta-analysis.","volume":"61","author":"Haarman","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"eoi230027r9","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/cxo.12584","article-title":"Contact lenses to slow progression of myopia.","volume":"100","author":"Sankaridurg","year":"2017","journal-title":"Clin Exp Optom"},{"issue":"5","key":"eoi230027r10","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1001\/jamaophthalmol.2022.0401","article-title":"Spectacle lenses with aspherical lenslets for myopia control vs single-vision spectacle lenses: a randomized clinical trial.","volume":"140","author":"Bao","year":"2022","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"eoi230027r11","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1097\/OPX.0000000000001410","article-title":"A 3-year randomized clinical trial of MiSight Lenses for myopia control.","volume":"96","author":"Chamberlain","year":"2019","journal-title":"Optom Vis Sci"},{"issue":"1","key":"eoi230027r12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/02713680590907256","article-title":"The longitudinal orthokeratology research in children (LORIC) in Hong Kong: a pilot study on refractive changes and myopic control.","volume":"30","author":"Cho","year":"2005","journal-title":"Curr Eye Res"},{"issue":"8","key":"eoi230027r13","first-page":"1110","article-title":"Myopia control effect of defocus incorporated multiple segments (DIMS) spectacle lens in Chinese children: results of a 3-year follow-up study.","volume":"106","author":"Lam","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"eoi230027r14","doi-asserted-by":"publisher","DOI":"10.1136\/bjo-2021-321005","article-title":"Control of myopia using diffusion optics spectacle lenses: 12-month results of a randomized controlled, efficacy and safety study (CYPRESS).","author":"Rappon","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"eoi230027r15","article-title":"Interventions to slow progression of myopia in children.","volume":"1","author":"Walline","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"eoi230027r16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/ICL.0000000000000677","article-title":"Biological mechanisms of atropine control of myopia.","volume":"46","author":"Upadhyay","year":"2020","journal-title":"Eye Contact Lens"},{"issue":"1","key":"eoi230027r17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41433-018-0139-7","article-title":"Update in myopia and treatment strategy of atropine use in myopia control.","volume":"33","author":"Wu","year":"2019","journal-title":"Eye (Lond)"},{"issue":"2","key":"eoi230027r18","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","article-title":"Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2).","volume":"119","author":"Chia","year":"2012","journal-title":"Ophthalmology"},{"issue":"3","key":"eoi230027r19","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10384-021-00822-y","article-title":"Efficacy and safety of 0.01% atropine for prevention of childhood myopia in a 2-year randomized placebo-controlled study.","volume":"65","author":"Hieda","year":"2021","journal-title":"Jpn J Ophthalmol"},{"issue":"9","key":"eoi230027r20","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/ceo.v50.9","article-title":"Low-concentration atropine eyedrops for myopia control in a multiracial cohort of Australian children: a randomized clinical trial.","volume":"50","author":"Lee","year":"2022","journal-title":"Clin Exp Ophthalmol"},{"issue":"9","key":"eoi230027r21","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.ophtha.2021.01.026","article-title":"Atropine for the treatment of childhood myopia in India: multicentric randomized trial.","volume":"128","author":"Saxena","year":"2021","journal-title":"Ophthalmology"},{"issue":"11","key":"eoi230027r22","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1001\/jamaophthalmol.2020.3820","article-title":"Safety and efficacy of low-dose atropine eyedrops for the treatment of myopia progression in Chinese children: a randomized clinical trial.","volume":"138","author":"Wei","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"eoi230027r23","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","article-title":"Low-Concentration Atropine for Myopia Progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control.","volume":"126","author":"Yam","year":"2019","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi230027r24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40268-013-0005-9","article-title":"Potential risks of pharmacy compounding.","volume":"13","author":"Gudeman","year":"2013","journal-title":"Drugs R D"},{"issue":"4","key":"eoi230027r25","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1378\/chest.13-0212","article-title":"Compounding pharmacy conundrum: \u201cwe cannot live without them but we cannot live with them\u201d according to the present paradigm.","volume":"143","author":"Guharoy","year":"2013","journal-title":"Chest"},{"issue":"12","key":"eoi230027r26","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1097\/ICL.0000000000000932","article-title":"Compounding of low-concentration atropine for myopia control.","volume":"48","author":"Richdale","year":"2022","journal-title":"Eye Contact Lens"},{"issue":"3","key":"eoi230027r28","doi-asserted-by":"publisher","first-page":"M184","DOI":"10.1167\/iovs.18-25977","article-title":"IMI: clinical management guidelines report.","volume":"60","author":"Gifford","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"eoi230027r29","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100923","article-title":"Efficacy in myopia control.","volume":"83","author":"Brennan","year":"2021","journal-title":"Prog Retin Eye Res"},{"issue":"13","key":"eoi230027r30","doi-asserted-by":"publisher","first-page":"7871","DOI":"10.1167\/iovs.13-12403","article-title":"Myopia stabilization and associated factors among participants in the Correction of Myopia Evaluation Trial (COMET).","volume":"54","author":"COMET Group","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"eoi230027r31","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/OPX.0000000000001367","article-title":"Myopia control: why each diopter matters.","volume":"96","author":"Bullimore","year":"2019","journal-title":"Optom Vis Sci"},{"issue":"2","key":"eoi230027r32","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","article-title":"Five-year clinical trial on Atropine for the Treatment of Myopia 2: myopia control with atropine 0.01% Eyedrops.","volume":"123","author":"Chia","year":"2016","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi230027r33","doi-asserted-by":"publisher","first-page":"22267","DOI":"10.1038\/s41598-021-01708-2","article-title":"Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial.","volume":"11","author":"Cui","year":"2021","journal-title":"Sci Rep"},{"issue":"4","key":"eoi230027r34","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1167\/iovs.02-0816","article-title":"A randomized clinical trial of progressive addition lenses vs single-vision lenses on the progression of myopia in children.","volume":"44","author":"Gwiazda","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"eoi230027r35","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1001\/archopht.122.11.1667","article-title":"Safety and efficacy of 2% pirenzepine ophthalmic gel in children with myopia: a 1-year, multicenter, double-masked, placebo-controlled parallel study.","volume":"122","author":"Siatkowski","year":"2004","journal-title":"Arch Ophthalmol"},{"issue":"8","key":"eoi230027r36","first-page":"4962","article-title":"Efficacy of NVK002 low-dose atropine for treatment of pediatric myopia progression over 24 months: comparison of CHAMP vs other published trials.","volume":"64","author":"Hemmati","year":"2023","journal-title":"IOVS"},{"issue":"9","key":"eoi230027r37","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1097\/OPX.0b013e31829cac92","article-title":"The risk of microbial keratitis with overnight corneal reshaping lenses.","volume":"90","author":"Bullimore","year":"2013","journal-title":"Optom Vis Sci"},{"issue":"1","key":"eoi230027r38","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/opo.v41.1","article-title":"Adverse event rates in the retrospective cohort study of safety of paediatric soft contact lens wear: the ReCSS study.","volume":"41","author":"Chalmers","year":"2021","journal-title":"Ophthalmic Physiol Opt"},{"issue":"9","key":"eoi230027r39","doi-asserted-by":"publisher","first-page":"6690","DOI":"10.1167\/iovs.10-7018","article-title":"Age and other risk factors for corneal infiltrative and inflammatory events in young soft contact lens wearers from the Contact Lens Assessment in Youth (CLAY) study.","volume":"52","author":"Chalmers","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"eoi230027r40","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1159\/000515568","article-title":"Myopia control with combination low-dose atropine and peripheral defocus soft contact lenses: a case series.","volume":"12","author":"Erdinest","year":"2021","journal-title":"Case Rep Ophthalmol"},{"issue":"9","key":"eoi230027r41","doi-asserted-by":"publisher","first-page":"259","DOI":"10.3390\/jcm7090259","article-title":"The synergistic effects of orthokeratology and atropine in slowing the progression of myopia.","volume":"7","author":"Wan","year":"2018","journal-title":"J Clin Med"},{"issue":"1","key":"eoi230027r42","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1177\/1120672121998903","article-title":"Low concentration atropine combined with orthokeratology in the treatment of axial elongation in children with myopia: a meta-analysis.","volume":"32","author":"Yang","year":"2022","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"eoi230027r43","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1186\/s12886-022-02635-0","article-title":"Combination of orthokeratology lens with 0.01% atropine in slowing axial elongation in children with myopia: a randomized double-blinded clinical trial.","volume":"22","author":"Yu","year":"2022","journal-title":"BMC Ophthalmol"},{"issue":"1","key":"eoi230027r44","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1186\/s13063-021-05825-1","article-title":"Efficacy of combined orthokeratology and 0.01% atropine for myopia control: the study protocol for a randomized, controlled, double-blind, and multicenter trial.","volume":"22","author":"Yuan","year":"2021","journal-title":"Trials"},{"key":"eoi230027r27","unstructured":"US Food and Drug Administration. Compounding and the FDA: questions and answers. Accessed July 12, 2022. https:\/\/www.fda.gov\/drugs\/human-drug-compounding\/compounding-and-fda-questions-and-answers"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2805504\/jamaophthalmology_zadnik_2023_oi_230027_1697215848.59622.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T15:11:17Z","timestamp":1697728277000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2805504"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,10,1]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2023.2097","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,1]]}}}